RDDA.F Dr. Reddy's Laboratories Limited

Healthcare Pharmaceuticals Frankfurt Exchange
13.10 EUR
Close of Nov 13, 2026
9.85 13.22
Market cap
EUR 10.9B
P/E
42.3x
P/B
2.99x
ROE
7.1%
Dividend yield
0.55%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is RDDA.F undervalued?

Graham number
Price13.10
Graham value5.53
Premium137.0%

RDDA.F trades 137.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dr. Reddy's Laboratories Limited fundamental analysis

No fundamental analysis for Dr. Reddy's Laboratories Limited yet.

Dr. Reddy's Laboratories Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished do…

Full company profile